Products for Research Use Only
RegisterLogin

Motesanib (Diphosphate)

CAT: 0804-HY-10229-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10229-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Motesanib Diphosphate (AMG 706 Diphosphate) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret.
CAS Number
857876-30-3
Product Name Alternative
AMG 706 (Diphosphate)
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
C-Kit; VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Motesanib-Diphosphate.html
Purity
99.86
Solubility
DMSO : ≥ 110 mg/mL|H2O : 5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1=CC=CN=C1NCC2=CC=NC=C2)NC3=CC(NCC4(C)C)=C4C=C3.O=P(O)(O)O.O=P(O)(O)O
Molecular Formula
C22H29N5O9P2
Molecular Weight
569.44
Precautions
H302, H315, H319, H335
References & Citations
[1]Polverino A, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 2006 Sep 1;66 (17) :8715-21.|[2]Kruser TJ, et al. Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors. Clin Cancer Res, 2010, 16 (14), 3639-3647.|[3]Coxon A, et al. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors. Clin Cancer Res, 2009, 15 (1), 110-118.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
VEGFR1/Flt-1; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4
Citation 01
Oncotarget. 2016 Sep 27;7 (39) :63839-63855.|Cell Physiol Biochem. 2018;48 (1) :227-236. |Harvard Medical School LINCS LIBRARY|J Cell Biochem. 2020 Mar;121 (3) :2343-2353.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.

Related Products

CatalogName
HY-10228-01Motesanib
HY-10228R-01Motesanib (Standard)
HY-W554614Diethylstilbestrol diphosphate
HY-112889Oxythiamine diphosphate
HY-131606Cidofovir diphosphate
HY-15296ACabergoline (diphosphate)
HY-147358-01Yimitasvir (diphosphate)
HY-B1831A-01Oritavancin (diphosphate)
HY-135867D-01NHC-diphosphate
HY-168165Adefovir diphosphate

Alternative Products

CatalogName
FM26093-01Motesanib diphosphate
BIFK0030-01Motesanib Diphosphate Salt
A10608-50Motesanib Diphosphate 50mg
A10608-10Motesanib Diphosphate 10mg
A10608-100Motesanib Diphosphate 100mg
A10608-5Motesanib Diphosphate 5mg
A5017-50Motesanib Diphosphate (AMG-706)

Popular Products